SCHEMBL21887014

SCHEMBL21887014

O=[N+]([O-])c1ccc(COCCN2CCOCC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 5/20 0.62
MAPT P10636 3/20 0.62
ALDH1A1 P00352 3/20 0.62
LMNA P02545 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
PKM P14618 2/20 0.53
KCNH2 Q12809 2/20 0.52
HRH3 Q9Y5N1 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
POLB P06746 2/20 0.49
THRB P10828 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
LTA4H P09960 1/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12128610 0.86 HRH3 (0.64) KCNJ1ALDH1A1LMNAKCNH2HRH3
SCHEMBL30435983 0.84 KCNJ1 (0.55) KCNJ1MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL24398649 0.82 TSHR (0.67) KCNJ1MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL12128477 0.82 KCNJ1 (0.50) KCNJ1MAPTALDH1A1SMN1; SMN2KCNH2
SCHEMBL852960 0.81 KCNJ1 (0.79) KCNJ1MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL4989061 0.81 KCNJ1 (0.69) KCNJ1MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL519451 0.81 LTA4H (0.71) KCNJ1MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL5321100 0.80 ATM (0.58) ALDH1A1KCNH2HRH3CYP1A2POLB
SCHEMBL2719675 0.80 HRH3 (0.69) KCNJ1MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL21887008 0.79 LTA4H (0.50) ALDH1A1LMNAKCNH2HRH3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112707907-B Purine derivative and intermediate thereof, and application of purine derivative and intermediate thereof in preparation of anti-cancer drugs 张飞 2023-05-23 CN disclosed
US-20220389017-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) 2022-12-08 US disclosed
US-20210340146-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) 2021-11-04 US disclosed
WO-2021078141-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE 苏州锐明新药研发有限公司 2021-04-29 WO disclosed
WO-2020063636-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG 苏州锐明新药研发有限公司 2020-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389017-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE PNP, ENTPD5, NTPCR KCNJ1 1888/4885MAPT 4875/4885ALDH1A1 999/4885
US-20210340146-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG PIK3CA, PIK3CD, PIK3R5 KCNJ1 832/4885MAPT 4752/4885ALDH1A1 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.